Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial

Jeremy Pettus, Dominic Reeds, Tricia S. Cavaiola, Schafer Boeder, Michelle Levin, Garry Tobin, Edda Cava, Dung Thai, Jim Shi, Hai Yan, Edgar Bautista, John McMillan, Roger Unger, Robert R. Henry, Samuel Klein

Research output: Contribution to journalArticlepeer-review

46 Scopus citations


The aim of the current study (Clinical trial reg. no. NCT02715193, clinicaltrials.gov) was to study the efficacy and safety of REMD-477, a glucagon receptor antagonist, in type 1 diabetes. This was a randomized controlled trial in which 21 patients with type 1 diabetes were enrolled. Glycaemic control and insulin use were evaluated in outpatient and inpatient settings, before and after a single 70-mg dose of REMD-477 (half-life 7-10 days) or placebo. Inpatient insulin use was 26% (95% CI, 47%, 4%) lower 1 day after dosing with REMD-477 than with placebo (P =.02). Continuous glucose monitoring during post-treatment days 6 to 12 showed that average daily glucose was 27 mg/dL lower (P <.001), percent time-in-target-range (70-180 mg/dL) was ~25% greater (~3.5 h/d) (P =.001), and percent time-in-hyperglycaemic-range (> 180 mg/dL) was ~40% lower (~4 h/d) (P =.001) in the REMD-477 group than in the placebo group, without a difference in percent time-in-hypoglycaemic-range (<70 mg/dL). No serious adverse events were reported. Glucagon receptor antagonism decreases insulin requirements and improves glycaemic control in patients with type 1 diabetes.

Original languageEnglish
Pages (from-to)1302-1305
Number of pages4
JournalDiabetes, Obesity and Metabolism
Issue number5
StatePublished - May 2018


  • diabetes
  • glucose homeostasis
  • glycaemic control, insulin


Dive into the research topics of 'Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial'. Together they form a unique fingerprint.

Cite this